Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 262

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Combination therapy of intraarterial 5‐fluorouracil and systemic interferon‐alpha for advanced hepatocellular carcinoma with portal venous invasion

Open access
Obi, Shuntaro, Yoshida, Haruhiko, Toune, Risa, Unuma, Tadao, Kanda, Miho, Sato, Shinpei, Tateishi, Ryosuke, Teratani, Takuma, Shiina, Shuichiro, Omata, Masao · 2006 · Cancer

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) with portal venous invasion (PVI) has a very poor prognosis, with a median survival of 3 months and virtually no survival at 1 year. The combination of intraarterial 5‐fluorouracil (FU) and systemic interferon‐α (IFNα) was recently reported to be effective against HCC with PVI, but these were small pilot studies. METHODS: One hundred and sixteen patients with HCC with PVI received IFNα (5,000,000 U intramuscularly on Days 1, 3, and 5 of each week of treatment) and 5‐FU (500 mg into hepatic artery on Days 1‐5 of the first and second week of each 4‐week cycle). The therapy was either terminated at the end of the first cycle in cases with progressive disease, or continued for at least 3 cycles, when responses to treatment were evaluated by Eastern Cooperative Oncology Group criteria. The survival rate was compared with that of historical controls (n = 40). RESULTS: Nineteen (16%) patients showed complete response and another 42 (36%) showed partial response. Adverse events were limited to nausea and appetite loss. The survival rates at 12 and 24 months among overall patients were 34% and 18%, respectively, in contrast to 15% and 5% among the historical controls. Survival rates at 12 and 24 months were 81% and 59% among complete responders, respectively, and 43% and 18% among partial responders. CONCLUSION: The combination therapy with 5‐FU and IFN was safe, and substantially improved the survival rate among the complete responders. These results provide a rationale for future randomized controlled trials. Cancer 2006. © 2006 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.21832

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 262

Metadata

Authors
Obi, S., Yoshida, H., Toune, R., Unuma, T., Kanda, M., Sato, S., Tateishi, R., Teratani, T., Shiina, S., & Omata, M.
Venue
Cancer
Publisher
Wiley
Published
2006-03-24
Volume
106
Issue
9
Pages
1990-1997
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2024802373
Cited by
262
References
17
FWCI
12.76
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combination therapy of intraarterial 5‐fluorouracil and systemic interferon‐alpha for advanced hepatocellular carcinoma with portal venous invasion. https://app.cochat.ai/papers/10.1002/cncr.21832
The paper
Obi, S., Yoshida, H., Toune, R., Unuma, T., Kanda, M., Sato, S., Tateishi, R., Teratani, T., Shiina, S., & Omata, M. (2006). Combination therapy of intraarterial 5‐fluorouracil and systemic interferon‐alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer. https://doi.org/10.1002/cncr.21832

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.